How to manage side effects to cabozantinib and nivolumab
This article gives some good advice about how to manage [...]
Government commits to a ‘stand-alone cancer strategy’
Great news yesterday when the Government committed to a 'stand-alone [...]
First CAR T-cell therapy for kidney cancer given Advanced Therapy designation by the FDA
The US Food and Drug Administration (FDA) has granted a [...]
National Kidney Cancer Audit for England and Wales
We are pleased to announce that the first ever National [...]
Belzutifan available on the NHS for patients with VHL disease
We are delighted to announce that the National Institute for [...]
Multi-million-pound UK-wide research into cancer immunotherapy
The Francis Crick Institute and The Royal Marsden NHS Foundation [...]
ASTRO 2024: SABR for primary kidney cancer – Is it ready for ‘primetime’?
In this presentation at the 2024 American Society for Radiation [...]
Clinical impact of the CARMENA trial on cytoreductive nephrectomy in the USA
A recent study looked at whether the use of cytoreductive [...]
Kidney Cancer Highlights from ESMO 2024
This year’s European Society for Medical Oncology (ESMO) Congress was [...]
Pazopanib plus bevacizumab shows promise as a first-line treatment for kidney cancer
Results from a phase 2 study of pazopanib alternated with [...]
